Thursday, 4 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    James Hardie Releases Annual Sustainability Report
    James Hardie Releases Annual Sustainability Report
    04/09/2025
    StudyIn Announces Completion of its Transaction with SUN Education
    StudyIn Announces Completion of its Transaction with SUN Education
    04/09/2025
    Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
    Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
    03/09/2025
    Coming Soon | GAC Will Officially Showcase Global Strategic Models at IAA Mobility 2025 in Munich
    Coming Soon | GAC Will Officially Showcase Global Strategic Models at IAA Mobility 2025 in Munich
    03/09/2025
    India’s Gaming Reset: New Law Sparks a Turning Point for the Industry, Says Redseer Strategy Consultants
    India’s Gaming Reset: New Law Sparks a Turning Point for the Industry, Says Redseer Strategy Consultants
    02/09/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • global
  • Business
  • july
  • today
  • announced
  • aug
  • company
  • Tech
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

ZEISS CLARUS 700 Receives NMPA Approval in China

PRNW Agency
Last updated: 06/06/2025 5:53 AM
PRNW Agency
Share
6 Min Read
ZEISS CLARUS 700 Receives NMPA Approval in China
SHARE
ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities

- Advertisement -

JENA, Germany and SHANGHAI, June 5, 2025 /PRNewswire/ — ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic’s retina workflow to support improved patient vision preservation. 

- Advertisement -

“ZEISS CLARUS 700 represents a major step forward in retinal imaging,” emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. “By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow.”

“Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients,” says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China.

- Advertisement -

Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2.  Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. 

- Advertisement -

More information about the CLARUS® 700 from ZEISS can be found here.

1 CLARUS 700#white-paper
2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). https://doi.org/10.1038/s41598-023-43947-5

- Advertisement -

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. 

- Advertisement -

Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.med@zeiss.com

Contact for the press
Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

- Advertisement -

www.zeiss.com/newsroom

- Advertisement -

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

- Advertisement -

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

- Advertisement -

For further information visit: www.zeiss.com/med

Photo – https://mma.prnewswire.com/media/2703671/Carl_Zeiss_Meditec_AG_zeiss_clarus_700.jpg
Logo – https://mma.prnewswire.com/media/546786/ZEISS_v1_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/zeiss-clarus-700-receives-nmpa-approval-in-china-302474013.html

- Advertisement -
Comviva Wins Gold at Brandon Hall Group HCM Excellence Awards 2025 for Learning and Development
Heavy Duty: Royal Mint Unveils Coin Celebrating Iron Maiden’s 50th Anniversary
JA Mining Expands Renewable Mining Infrastructure in North America Post Completion of Independent Security Audit
SciSparc: AutoMaxs Shareholders Approve Merger with SciSparc
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: SNAP BENEFITS LINKED TO SLOWER COGNITIVE DECLINE, 10-YEAR STUDY FINDS
TAGGED:administrationangiographyannouncedapprovalcapabilitieschinaclarus®expandsfluoresceingermanyhighresolutionimaginginsightsjenajunemedicalnationalnmpaophthalmologistsproductsreceivedretinaretinalshanghaiTechnologytodayultrawidefieldworkflowzeiss
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Atos – Half-year 2025 results on track. Full Year 2025 targets confirmed
Tech

Atos – Half-year 2025 results on track. Full Year 2025 targets confirmed

01/08/2025
ZTE’s “Signal Reach Program” Wins WSIS 2025 Champion Award
Entertainment

ZTE’s “Signal Reach Program” Wins WSIS 2025 Champion Award

10/07/2025
Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
Business

TOPPAN Security Strengthens Market Leadership in Asia with Acquisition of dzcard Group

04/06/2025
Max India Limited’s Rights Issue: 1.45 Times Oversubscription Signals Strong Investor Confidence
Business

Max India Limited’s Rights Issue: 1.45 Times Oversubscription Signals Strong Investor Confidence

31/05/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?